ok la big boss sapu

Strategic Collaboration Agreement I

TRSB and SMEQ shall be exclusively responsibleand to develop the New Business as set out in the Strategic Collaboration Agreement I in their specified territory as follows:-TRSB: Malaysia, Singapore, Indonesia, Thailand and AustraliaSMEQ: China(i)TRSB's responsibility and contributionTRSB shall be responsibleinthe area of medical related real estateby providinginfrastructures, land and facilities for the medical operators recommended by SinopharmGroup or SMEQ pertaining to the New Business.(ii)SMEQ's responsibility and contributionSMEQ undertakes to supply the medical and hospital equipment and products under the New Businessas set outin the Strategic Collaboration Agreement I.

Strategic Collaboration Agreement II

(i)TRSB's responsibility and contributionTRSB undertakes to provide funding to meet the financing conditions for the constructionbaseand be responsible for the related development and construction conditions of the construction base for the purpose of the New Business as set out in Strategic Collaboration Agreement II. (ii)SINOMACH's responsibility and contributionSINOMACH undertakes to assist TRSB in sourcing for funding, and to provide resources in any manners, at the constructionbase, for the supply of equipment, technological and technical support for the New Business.

Strategic Collaboration Agreement III

Rubberex shall sell, and TRSB shallbuy gloves from Rubberex, and export to theChina market via SMEQ. Further, TRSB shall distributeandimport the personal protection equipment and medical products from SMEQ, and sell to Rubberex.The Board anticipates that the net profit attributable to the New Business may contribute more than 25.0% of the total net profit of TitijayaGroup in the financial years moving forward.Accordingly, the Board proposes to seek for the approval from the shareholders of Titijayaat an extraordinary general meeting ("EGM") to be convened for the Proposed Diversification pursuant to Paragraph 10.13(1) of the Main Market Listing Requirements of Bursa Malaysia SecuritiesBerhad ("Bursa Securities")("Listing Requirements"). Notwithstanding the Proposed Diversification, the Board intends to continue with the existing business activities of TitijayaGroup in the same manner.

sinopharm ok....HUGE deal ;-P...bagi limit up can?

KUALA LUMPUR (Aug 12): Rubberex Corp Bhd has signed a distribution agreement with a unit of Titijaya Land Bhd to export gloves, personal protection equipment and medical products to China.

In a filing with Bursa Malaysia today, the glove maker said it aims to distribute and export the products to the China market via Sinopharm Medical Equipment QuanZhou Co Ltd.

Rubberex entered into the agreement today with Titijaya Resources Sdn Bhd (TRSB), which is principally engaged in the trading of medical equipment and products, as well as property development.

It said if necessary, a special purpose corporate vehicle will be incorporated.

“The agreement shall be valid for a period of 12 months from the date of the agreement or any extended period as may be agreed between Rubberex and TRSB,” it said.

Shares of Rubberex fell RM1.12 or 19% to RM4.77, valuing the company at RM1.32 billion. The counter has shot up by some 783% this year.

hehe fly fly fly

beutiful rebound....hope can continue upwards tmr

https://www.theedgemarkets.com/article/singapore-firm-obtains-majority-stake-melaka-project-hatten-land-part-us323m-deal

singapore investor so bullish with Hatten project in melaka......this yong tai why half dead

today sapnrg vol probably a record of bursa?

Come on guys. All make money all happy la ok don't quarrel over small issues

KYY sure heart pain

need to pay US RM53 MIL....sap sap sui

hope they push this like GUNUNG LOL

https://malaysiastock.biz/Company-Announcement.aspx?id=1249425

JV with GUNUNG for state project...no wonder fly

hehehe

GENEVA (Aug 7): Six Covid-19 vaccine candidates, including three from China, have entered Phase 3 trials, reported the Xinhua News Agency, quoting senior World Health Organization (WHO) official yesterday.

The three Chinese candidates are from Sinovac, Wuhan Institute of Biological Products/Sinopharm, and Beijing Institute of Biological Products/Sinopharm, said Michael Ryan, the executive director of the WHO Health Emergencies Programme, at a virtual briefing.

The other three are made by the University of Oxford/AstraZeneca, Moderna/NIAID, and BioNTech/Fosun Pharma/Pfizer, he added.

The vaccines will be put into the general population for the first time in Phase 3 after previous trials focused on safety, immunogenicity and immune response in a small number of humans, said the WHO official. The Phase 3 trial will test whether the vaccines can "protect large numbers of people over a prolonged period of time".

https://www.theedgemarkets.com/article/six-covid19-vaccine-candidates-including-three-china-now-phase-3-trials-%E2%80%94-who

all penny moves even for elephants like trive and eduspec...this will be next ;-)

its an agreement....not MOU

KUALA LUMPUR (April 29): Titijaya Land Bhd has inked a five-year agreement with a Chinese state-owned medical equipment manufacturer to develop a business that will be involved in the trading and distribution of medical and hospital equipment, as well as medical industry-related real estate.

In a bourse filing, the group said its wholly-owned Titijaya Resources Sdn Bhd (TRSB) had inked the strategic collaboration agreement with Sinopharm Medical Equipment QuanZhou Co. Ltd (SMEQ), which is part of Sinopharm China National Medical Device Company, whose holding company is China National Pharmaceutical Group Corp (Sinopharm Group).

"Sinopharm Group is a large healthcare group directly under the State-owned Assets Supervision and Administration Commission (SASAC) of the State Council, with a full chain in the industry covering R&D (research and development), manufacturing, logistics and distribution, retail chains, healthcare, engineering services, exhibitions and conferences, international business and financial services," said Titijaya.

The main, immediate focus of the collaboration will be the supply of equipment such as personal protection equipment (PPE), RT-PCR (real-time reverse transcription polymerase chain reaction) test kits, rapid test kits, mobile test labs and other necessary equipment needed to combat Covid-19.

Under the agreement, Titijaya said TRSB and SMEQ will collaborate to develop the business by leveraging on the supply and value chain of Sinopharm Group and SMEQ in China, as well as the networks of TRSB and Sinopharm Group.

“For other businesses of Sinopharm Group not within the scope of business of SMEQ, SMEQ will assist TRSB to develop such scope of business by coordinating with Sinopharm Group to accommodate the demands of TRSB,” Titijaya said.

TRSB, meanwhile, will be responsible to provide infrastructure, land and facilities for medical industry operators recommended by Sinopharm Group or SMEQ.

The agreement can be renewed for another five-year term, subject to agreement by both parties.

Titijaya shares closed unchanged at 26 sen apiece today, giving it a market capitalisation of RM352.37 million. It saw 304,100 shares changing hands.

lets not talking about contract first....we are talking about building the vaccine hub here....tats why titijaya being property company beneficial too

so many people revealing their personal phone numbers thanks to paktua lol

they already in partnership with sinopharm

Absurd if u think their jv company won't get approval from government

https://www.theedgemarkets.com/article/titijaya-teams-chinas-stateowned-healthcare-group-sinopharm-supply-ppes-test-kits

Read above links. They also will collaborate on medical real estate. So the medicine/vaccine hub already in planning since april

titijya with sinopharm are way more convincing than HWGB with that unknown company........

https://news.cgtn.com/news/2020-08-07/Six-COVID-19-vaccine-candidates-in-phase-3-trials-3-from-China-WHO-SKLR0O8auQ/index.html

Six COVID-19 vaccine candidates, including three from China, have entered phase-3 trials, a senior World Health Organization (WHO) official said on Thursday.

The three Chinese candidates are from Sinovac, Wuhan Institute of Biological Products/Sinopharm and Beijing Institute of Biological Products/Sinopharm, said Michael Ryan, executive director of the WHO Health Emergencies Program, at a virtual briefing.

The other three are made by the University of Oxford/AstraZeneca, Moderna/NIAID and BioNTech/Fosun Pharma/Pfizer, he added.

The vaccines will be put into the general population for the first time in phase 3, after previous trials have focused on safety, immunogenicity and immune response in a small number of humans, said the WHO official. The phase-3 trial will test whether the vaccines can "protect large numbers of people over a prolonged period of time."

However, "phase-3 doesn't mean nearly there," he said, as "there is no guarantee that any of these six will give us the answer."

In total, 165 vaccine candidates have started some forms of trials, and 26 of them in clinical trials, according to WHO records.

if one not greedy...everyday also can make money

EGM next week for consolidation

well....operators sold down all healthcare counters this afternoon....nothing to do with supermx results

next week should be vaccine play lead by HWGB

THERE is a prospect for Malaysia to become the hub of manufacturing Covid-19 vaccine for countries in the Asean region.

Health DG Datuk Dr Noor Hisham Abdullah (picture) said Malaysia is engaging with China to discuss issues related to the virus, one of the topics is the vaccine.

He said there are three companies that are looking into the vaccine development namely Sinovac Biotech Ltd, Sinopharm Group (Holding) Co Ltd and CanSino Biologics Inc, and they are in the clinical trial.

“Initially, we wanted Malaysia to be the hub of clinical trials but we do not have many patients now to do it, so they are taking the research to Brazil.

“If they find strong evidence that suggests the vaccine works, we would like to volunteer to be the hub of manufacturing for Asean countries, so that’s another ongoing negotiation. Having said that, we need to look into the data first before we can make any conclusive action,” he said in a webinar entitled “How Can Asean Bounce Back: Fostering Public Health Safety and Economic Resilience for a Borderless Community in Asean” recently.

The webinar was hosted by CIMB Asean Research Institute under its Covid-19 Economic Recovery Plan Series.

When asked if Malaysia has the capacity to manufacture the vaccine, Dr Noor Hisham said there is no doubt that Malaysia can be the hub of manufacturing, but that they need to see the data before making any decision.

i think most didnt know the news.....

prlexus ALWAYS fails to hold on to the gain

see how useless is this.....

director keep selling warrant tats why

the worst performing face mask counter lol

AT denied about the 3 party deal

wah didnt realized this flew too

beautiful closing...broke resistance

see if 18.00 can support

miche87.....which guru taught u by just compare price like that lol

can fly like iconic or not lol

lol jingle bell love eduspec so much he/she only commenting 100% on eduspec

might has been priced in...i doubt anybody bought AAX last few weeks anticipating its good results considered how bad airasia the mother's results....anyway AAX now is more of a technical play....not fundamental

Mr mak AT still dilly dally with glove ...this one can kah

terminated term sheet? unsatisfactory due diligence...so gg? lol

lol magic show

oh sabah assembly dissolved......no wonder this move

almost broke 0.070

has not reached the bottom, which is around 0.080......

more than 10% of t0tal shares